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Abstract
Introduction Previous studies indicate that overexpression of
the membrane-associated mucin MUC4 is potently anti-
adhesive to cultured tumor cells, and suppresses cellular
apoptotic response to a variety of insults. Such observations
raise the possibility that MUC4 expression could contribute to
tumor progression or metastasis, but the potential involvement
of MUC4 in breast cancer has not been rigorously assessed.
The present study aimed to investigate the expression of the
membrane mucin MUC4 in normal breast tissue, primary breast
tumors and lymph node metastases, and to evaluate the role of
MUC4 in promoting the malignant properties of breast tumor
cells.
Methods MUC4 expression levels in patient-matched normal
and tumor breast tissue was initially examined by
immunoblotting lysates of fresh frozen tissue samples with a
highly specific preparation of anti-MUC4 monoclonal antibody
1G8. Immunohistochemical analysis was then carried out using
tissue microarrays encompassing patient-matched normal
breast tissue and primary tumors, and patient-matched lymph
node metastases and primary tumors. Finally, shRNA-mediated
knockdown was employed to assess the contribution of MUC4
to the cellular growth and malignancy properties of JIMT-1
breast cancer cells.
Results Immunoblotting and immunohistochemistry revealed
that MUC4 levels are suppressed in the majority (58%, p <
0.001) of primary tumors relative to patient-matched normal
tissue. On the other hand, lymph node metastatic lesions from
37% (p < 0.05) of patients expressed higher MUC4 protein
levels than patient-matched primary tumors. MUC4-positive
tumor emboli were often found in lymphovascular spaces of
lymph node metastatic lesions. shRNA-mediated MUC4
knockdown compromised the migration, proliferation and
anoikis resistance of JIMT-1 cells, strongly suggesting that
MUC4 expression actively contributes to cellular properties
associated with breast tumor metastasis.
Conclusions Our observations suggest that after an initial loss
of MUC4 levels during the transition of normal breast tissue to
primary tumor, the re-establishment of elevated MUC4 levels
confers an advantage to metastasizing breast tumor cells by
promoting the acquisition of cellular properties associated with
malignancy.
EDTA: ethylenediaminetetraacetic acid; ER: estrogen receptor; HER: human epidermal growth factor receptor; PBS: phosphate-buffered saline; PR: 
progesterone receptor; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMA: tissue microarray.Breast Cancer Research    Vol 11 No 5    Workman et al.
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Introduction
Mucins comprise a large family of cell surface and secreted
proteins most commonly expressed by epithelial cells [1], but
they are also associated with other cell types such as the
endothelial lining of vascular spaces [2,3]. Mucins are present
on the apical surface of epithelial cells of gastro-intestinal, res-
piratory, breast, and reproductive tissues, and contribute to tis-
sue lubrication, hydration, and protection. Mucins are defined
by a serine/threonine-rich region within their extracellular
domains that is heavily O-glycosylated, and the abundant O-
linked glycans are largely responsible for the physico-chemical
properties of mucins that contribute to epithelial protection
[4,5]. It has recently become appreciated that a subset of
these proteins, the membrane mucins that are physically teth-
ered to the plasma membrane via a transmembrane domain,
are capable of stimulating intracellular signaling pathways to
contribute to cellular growth regulation [6-8].
MUC4, a membrane mucin, is a non-covalently linked het-
erodimeric protein complex composed of the two subunits
MUC4α and MUC4β arising from a single transcript. The enor-
mous extracellular MUC4α subunit contains an O-glycosyla-
tion domain and a nidogen-related domain, followed by an
AMOP domain towards the C-terminus. Glycans attached to
repeating units within the O-glycosylation domain of the
MUC4α subunit dominate the mass of MUC4, and contribute
to its protective and anti-adhesive properties. The much more
modest-sized MUC4β transmembrane subunit contains a von
Willebrand factor D domain, and three epidermal growth fac-
tor-like domains that lie N-terminal to the transmembrane
domain; these domains may be involved in protein-protein
interactions that contribute to MUC4 function [9-11]. A func-
tion for the short (about 20 amino acids) cytoplasmic tail of the
MUC4β subunit has yet to be described [12].
MUC4 expression has been reported in a variety of well-differ-
entiated epithelial tissues in the adult including gastrointestinal
tract, breast [13,14], and lung [15,16]. MUC4 expression has
also been reported in a variety of carcinomas including ovarian
[17,18], lung [15,19], pancreatic [20,21], gall bladder [22],
and breast [23]. These observations are significant because
MUC4 has been demonstrated to potentiate signaling by
ErbB2 [9,11], a receptor known to contribute to the malig-
nancy of breast and ovarian tumors, as well as other tumor
types. In addition, the anti-adhesive [24] and anti-apoptotic
[12,25] properties of overexpressed MUC4 could provide
tumor cells with a selective growth or survival advantage.
Indeed, ectopic overexpression of rat MUC4 in a human
melanoma model cell line increased primary tumor growth [25]
and metastasis [26] efficiencies when introduced into nude
mice.
Although work examining the impact of MUC4 on model tumor
cell properties strongly supports the notion that the mucin can
promote tumor progression, evidence that it might do so in
human tumors has been harder to obtain. For example, while
many studies document MUC4 expression in tumors, often
analysis of matched normal tissue is lacking, raising questions
as to the extent to which MUC4 is dysregulated in tumors.
Moreover, the interpretation of expression studies has been
hampered by the use of incompletely characterized antibodies
that may not be entirely specific for MUC4. Here we develop
a reliable reagent for the assessment of MUC4 expression in
human tissues, and apply it to examine MUC4 expression in
normal breast tissue, as well as in primary tumors and lymph
node metastases. Unexpectedly, we find that MUC4 expres-
sion tends to be reduced in primary tumors relative to normal
tissue, but is regained upon metastasis. Thus, re-expression of
MUC4 by metastasizing cells could significantly augment their
malignancy. Indeed, we further demonstrate that the presence
of endogenous MUC4 in a cultured breast tumor line derived
from a pleural metastasis promotes cell migration, proliferation
and resistance to anoikis.
Materials and methods
Cell lines and cell culture
Human breast cell lines MCF10A, MCF7, MDA-MB-453,
MDA-MB-435, MDA-MB-468, MDA-MB-231, MDA-MB-361,
SKBR3, T47D, BT474, rat mammary tumor cell line MATB-III,
and HEK293T cells were purchased from the American Type
Culture Collection and cultured in their recommended media
(Mediatech, Manassas, VA, USA). The JIMT-1 human breast
cancer cell line [27] and its MUC4 knockdown derivative [12]
have been previously described. A375-Rep8 and MCF7-Rep5
cells inducibly expressing rat MUC4 have been previously
described [11,24]. Construction of the human breast cell line
MCF10A-h MUC4/Y inducibly expressing the human MUC4/
Y variant will be described elsewhere (Workman et al., in
preparation).
Immunoblotting experiments
Primary antibodies were from the following sources: anti-
MUC4 mouse monoclonal antibody 1G8s was used as condi-
tioned media from hybridoma line #2D10, clone HL1718, and
1G8c was purchased from Zymed (Carlsbad, CA, USA); anti-
MUC4 antibodies 8G7, P-20 and H-300 were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); anti-actin
and anti-α-tubulin were from Sigma (St. Louis, MO, USA).
Horseradish peroxidase-conjugated secondary antibodies
were from Invitrogen (Carlsbad, CA, USA), and SuperSignal
West developing chemicals were from Pierce (Rockford, IL,
USA). An Alpha Innotech (San Leandro, CA, USA) imaging
station with FluorChem software was used to capture and
quantify images.
Human breast tissue analysis
Fresh frozen human tissues from clinical samples were pro-
vided by the National Cancer Institute Cooperative Human Tis-
sue Network and the National Cancer Institute-funded UCAvailable online http://breast-cancer-research.com/content/11/5/R70
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Davis Cancer Center Biorepository, and were used in western
blotting experiments. All of the samples were approved for lab-
oratory use by the Institutional Review Board of the UC Davis
School of Medicine. Samples were homogenized in 10 μl T-
Per (Pierce, Rockford, IL, USA) per mg of tissue in the
presence of 4 μg/ml leupeptin, 4 μg/ml pepstatin, 4 μg/ml
aprotinin, and 100 nmol 4-(2-aminoethyl) benzenesulfonyl flu-
oride, and then centrifuged to remove insoluble products.
Cleared lysates were added to sample buffer and analyzed by
immunoblotting.
Specificity of immunohistochemical immunoreactivity
Immunoreactivity was compared in cell lines expressing and
not expressing MUC4. MCF10A-hMUC4/Y and A375-rRep8
cells stably expressing inducible MUC4 were treated with 100
ng/ml and 2 μg/ml tetracycline (Sigma, St. Louis, MO, USA) to
induce and repress expression, respectively. JIMT-1-pSuper-
shRNAi-hMUC4 and JIMT-1-pSuper-shRNAi-scramble stably
transduced cell lines [12] were compared with assess endog-
enous MUC4 expression. In each case, cells grown to about
70% confluency were scraped, pelleted by centifugation, fixed
in 10% buffered formalin for one hour, stored in 70% ethanol
and ultimately paraffin embedded.
Tissue micro-array staining
Unstained human tissue micro-array (TMA) slides BR451,
BR480, BR481, BR701, BR721, BR722, BR801, BR1001,
and BR1003 (with no overlapping cases) were purchased
from US Biomax (Rockville, MD, USA). TMA samples had a
core size of 1 to 2 mm and each core had a thickness of 5 μm.
Matched assays containing normal tissues typically consisted
of adjacent uninvolved tissue taken approximately 1.5 cm from
primary tumor. Unmatched normal breast tissue came from
patients of good health. TMAs were prepared as suggested by
the manufacturer using the UltraVision LP Detection System
(Thermo Scientific, Pittsburgh, PA, USA). Slides were depar-
affinized with xylene and rehydrated with alcohol. Slides were
incubated in 3% H2O2 (in deionized water) for 10 minutes to
suppress endogenous peroxidase activity. Antigen retrieval
was carried out by incubating slides in 1 mM ethylenediamine-
tetraacetic acid (EDTA), pH 8.0, for 15 minutes at 98°C.
Slides were incubated for 1.5 hours with 1:25 1G8s, and
counterstaining was performed using ImmunoMaster Hema-
toxylin (American MasterTech, Lodi, CA, USA). Immunoreac-
tivity levels were assigned a value on a 0 to 3 scale (see
below). Images were captured on an Olympus BX-40 using
DP2-BSW software (Center Valley, PA, USA).
Expression analysis
Samples were examined by the primary author (HCW) and
two additional pathologists/authors (ADB and RDC). Results
were compiled and statistics were provided by an author stat-
istician (LAB). Paired samples (normal vs. primary tumor or pri-
mary tumor vs. metastasis) were analyzed in two
complementary ways. First, the fraction of times one sample
within a pair stained more intensely exceeded 50% was
tested; McNemar's test was used, excluding cases where
both stained equally, and calculated the exact two-sided bino-
mial probability for a disparity as extreme or more extreme if the
true proportion were 0.5. Next, the difference in the mean
staining score was tested, and the staining levels 0, 1+, 2+
and 3+ were treated as scale values and a paired t-test to test
whether the mean difference was zero was used. All tests
were two-sided at level 0.025, to ensure experiment-wise error
rate below 0.05 that allowed for two comparisons (normal to
primary tumor; primary tumor to metastasis). Individual data
samples for immunoreactivity intensity from patients with
tumor, normal tissue, or metastatic tumor were also compared.
For these groups of patients, we carried out independent sam-
ples t-tests to compare the mean immunoreactivity levels
between groups (patients with normal vs. those with primary
tumor; patients with primary tumor vs. those with metastatic
tumor). Again, all tests were two-sided at level 0.025.
Migration assay
JIMT-1 scramble and knockdown cells were seeded in tripli-
cate at 4 × 104 cells per well in 24-well Boyden chambers with
8 μm pore polycarbonate membranes (Corning, Corning, NY,
USA), using complete media in the upper chamber and serum
starve media in the lower chamber. After 16 hours, the lower
chamber was replaced with complete media and the upper
chamber replaced with serum starve media. Cells were
allowed to migrate for 18 hours, filters were fixed, stained
using the Diff-quik system (Dade Behring, Newark, USA), and
photographed using an Olympus DP70 200× objective and
DP Controller software (Center Valley, PA, USA). Three fields
of view for each well were quantified by counting all the cells
in each field and averaging the results for each condition.
Anoikis and cell cycle analyses
JIMT-1 derivatives were plated in ultra-low attachment 60 mm
or 100 mm flat-bottom plates (Corning, Corning, NY, USA) in
complete media containing 1% methyl cellulose (Sigma, St.
Louis, MO, USA), and grown for 96 hours. Suspended cells
were then collected by centrifugation, washed in PBS, and
fixed in 4% paraformaldehyde for one hour followed by 70%
ethanol for one hour to overnight at 4°C. Cells were then
rinsed in PBS and incubated for 30 minutes in propidium
iodide solution (Sigma, St. Louis, MO, USA), EDTA, RNAse,
and spermine (Sigma, St. Louis, MO, USA) SubG1 and cell
cycle analysis of 15,000 to 30,000 cells per sample was car-
ried out using a Becton-Dickinson fluorescent-activated cell
sorting scanner using Cellquest software by Becton Dickinson
(Oakville, Ontario, Canada) and ModFit software vy Veity (Top-
sham, ME, USA). Anoikis data is presented as a Forest meta-
analysis plot [12]. Odds ratios were calculated using the sub-
G1 positive and non-positive populations for cells harboring
scrambled and MUC4 knockdown shRNAs and plotted using
Graphpad Prism software (La Jolla, CA, USA).Breast Cancer Research    Vol 11 No 5    Workman et al.
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Results
Identification of the 100 kDa MUC4β subunit using 
monoclonal antibody 1G8
In an effort to identify an antibody that would be useful in
assessing MUC4 expression in human breast tissue samples,
we first screened a spectrum of antibodies for their abilities to
specifically immunoblot MUC4 in cultured breast cell lines.
We observed that many commercially available antibodies,
including H-300, P20, and 8G7, exhibited marginal specific
blotting and/or multiple background bands (not shown). Mon-
oclonal antibody 1G8, raised to the beta subunit of rat MUC4
[28], has been previously reported to detect human MUC4 in
various tissues and cell lines [2,3,12,29]. However, we
observed that 1G8 obtained from a commercial source, which
we call 1G8c, recognized a very prominent non-specific band
of about 135 kDa in all cell lines, but only weakly recognized
rat MUC4 inducibly expressed in human MCF7 breast cancer
cells (Figure 1a). The reactivity of these antibody preparations
with unrelated proteins calls into question results that might be
obtained with their use in the immunohistochemical character-
ization of tissue samples.
In contrast, conditioned media from the 1G8 hybridoma, which
we call 1G8s, recognized a single band of about 100 kDa that
was prominently expressed in JIMT-1 cells, modestly
expressed in T47D cells (Figure 1b), and expressed at very
low levels in SKBR3 and BT474 cells (not shown). No evi-
dence of the non-specific band of about 135 kDa was
observed with 1G8s. As expected, 1G8s recognized a single
band of about 145 kDa in rat 13762 MATB-III mammary tumor
cells, corresponding to the heavier rat MUC4β form to which
the antibody was originally raised [28]. Importantly, the band
of about 100 kDa was lost when human JIMT-1 cells were sta-
bly transduced with MUC4-directed shRNA in a retroviral vec-
tor (Figure 1c). Finally, 1G8s recognized a pair of bands at
about 160 kDa and about 120 kDa in 293T cells transiently
transfected with human MUC4/Y, an alternatively spliced form
of MUC4 lacking much of the alpha subunit [20,30,31]. These
bands were also suppressed by MUC4-directed shRNA (Fig-
ure 1d), and most likely correspond to uncleaved MUC4/Y and
MUC4/Y cleaved into its beta and residual alpha subunits.
Together, these results suggest that the 1G8s preparation
specifically recognizes human MUC4 in breast cancer cells,
and will be useful in the analysis of human breast tissue
samples.
Loss of MUC4 expression in primary breast tumors
To determine whether MUC4 expression is dysregulated in
human breast tumors, we first immunoblotted tissue lysates of
primary tumor samples from breast cancer patients with the
1G8s preparation. Consistent with a previous report that con-
cluded that MUC4 is expressed in 95% of breast cancers on
the basis of immunohistochemical staining [23], we detected
the presence of the MUC4β band of about 100 kDa in 59 of
70 (84%) of tumors (Figure 2), although the relative levels of
MUC4β protein varied considerably among tumor samples.
Figure 1
Characterization of 1G8 antibodies Characterization of 1G8 antibodies. (a) Whole cell lysates from the indicated breast epithelial cell lines were resolved by 8% SDS-PAGE and blot-
ted with commercially obtained anti-MUC4 antibody 1G8 (1G8c). MCF7-Rep5 is a human breast cancer line stably expressing inducible rat MUC4 
(24). (b) Cell lysates were resolved by 6% to 12% gradient SDS-PAGE and immunoblotted with supernatant from cultured 1G8 hybridoma (1G8s) 
or with anti-tubulin. The MATB-III rat mammary adenocarcinoma cell line was used as a positive control for MUC4 expression (12, 44, 45). (c) Wild-
type JIMT-1 or JIMT-1 cells stably transduced with MUC4 shRNA were blotted with 1G8s and actin. (d) HEK293T cells were transiently co-trans-
fected with pLenti vector control or pLenti-hMUC4/Y vector, together with pSuper vector control (v) or MUC4 shRNA (M4) or scrambled (scr) oligo-
nucleotides in pSuper. Lysates were blotted with 1G8s and actin.Available online http://breast-cancer-research.com/content/11/5/R70
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Moreover, because only modest amounts of material were
available for some samples, reflected in low actin content by
immunoblotting, the figure of 84% must be considered to be a
lower limit for the extent of Muc4 expression in breast tumors.
Unexpectedly, however, when we compared patient-matched
normal and tumor tissue by immunoblotting, we observed a
marked decrease of MUC4β protein in all tumors relative to
adjacent normal tissue. In the experiments illustrated in Figure
3, a total of 14 patient-matched tumor and adjacent normal tis-
sues were compared by immunoblotting with 1G8s. Loss of
MUC4β was a common feature of all tumors surveyed, and
appeared to be independent of tumor grade, or estrogen
receptor (ER), progesterone receptor (PR) or human epider-
mal growth factor receptor (HER) 2 status (Figure 3a). Some
sample pairs were run side by side with lysates from JIMT-1
cells (Figure 3b), demonstrating that the band blotted in
tumors is identical in migration to the band of about 100 kDa
that can be knocked down with MUC4-directed shRNA. These
observations indicate that the loss of MUC4β protein may be
a feature common to the transition from normal mammary epi-
thelial tissue to tumor, and are consistent with a model
whereby MUC4 protein expression is suppressed upon dedif-
ferentiation of epithelial cells.
Immunohistochemical analysis of human breast tumors
To examine patterns of MUC4 protein expression in breast
tumors, we first optimized the 1G8s antibody preparation for
immunohistochemical reactivity toward MUC4-expressing cul-
tured cells. Under optimal conditions 1G8s stained rat MUC4
inducibly expressed in A375 melanoma cells (Figure 4a),
revealing a uniform cell surface expression pattern in all cells
of the field. In addition, 1G8s stained inducible human MUC4/
Y stably expressed in MCF10A cells (Figure 4b). Finally, 1G8s
staining of endogenous MUC4 in JIMT-1 cells was markedly
diminished when MUC4 expression was knocked down (Fig-
Figure 2
Presence of MUC4β in primary human breast tumors Presence of MUC4β in primary human breast tumors. Tissue lysates from 70 human primary breast tumors were immunoblotted with 1G8s and 
actin.Breast Cancer Research    Vol 11 No 5    Workman et al.
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ure 4c). These observations strongly suggest that 1G8 specif-
ically recognizes MUC4 by immunohistochemistry.
To assess MUC4 expression in breast tissue, we examined
nine commercially obtained TMAs encompassing over 600
samples of individual and patient-matched normal tissue, pri-
mary tumor and lymph node metastases. Immunohistochemi-
cal staining of each sample by 1G8s was assigned a score of
0 to 3+ as follows: 0, no stain to less than 30% of cells stain-
ing faintly; 1+, greater than 30% of cells staining light to mod-
erate; 2+, greater than 50% of cells staining moderately; 3+,
intense staining of majority of the epithelial population (Figure
5). Blood vessels served as internal positive controls, because
it has been previously shown that endothelial cells express
abundant MUC4 [2,3]. Samples whose vessels stained nega-
tive or only faintly positive were not included in the statistical
analysis.
Table 1 summarizes our analysis, listing sample types and
average MUC4 staining intensities; the upper tier represents
our analysis of individual samples, while the lower tier repre-
sents our analysis of patient-matched paired samples. In gen-
eral, there was very good agreement in average MUC4
staining intensity of normal, primary tumor, and metastatic
tissue between the two groups. Consistent with our immuno-
blotting results, MUC4 expression was significantly greater (P
< 0.001) in normal tissue than primary tumor, whether looking
at individual or paired samples. In the paired samples, 57.5%
of primary tumors exhibited suppressed MUC4 levels relative
to patient-matched normal tissue, while 11% overexpressed
mucin. The intensity and pattern of MUC4 staining in primary
tumors was not significantly associated with HER2, ER, PR, or
p53 status, nor was it associated with tumor stage or grade
(not shown). Importantly, in both individual and paired analyses
MUC4 expression was significantly higher (P < 0.05) in meta-
static lesions than in primary tumors, suggesting that MUC4
re-expression may be common to breast tumor metastasis. In
the paired samples, 37.2% of lymph node metastases
expressed higher MUC4 levels than patient-matched primary
tumors, while only 9.3% expressed lower levels. These obser-
vations point to a strong tendency for metastasized breast
tumors to overexpress MUC4 relative to primary tumors, per-
Figure 3
MUC4 expression is consistently suppressed in the normal-to-tumor transition MUC4 expression is consistently suppressed in the normal-to-tumor transition. (a) Lysates from eight patient-matched normal and tumor tissue sam-
ples, four representing grade II tumors and four representing grade III tumors, were immunoblotted with 1G8s and anti-actin (right panels). Pathology 
analysis of patient tumor samples, including estrogen receptor (ER), progesterone receptor (PR) and human eipdermal growth factor receptor (HER) 
2 status, are provided in the table. (b) Lysates from six independent patient-matched normal and tumor tissues were analyzed side by side with JIMT-
1 cell lysates.Available online http://breast-cancer-research.com/content/11/5/R70
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haps pointing to a functional role for MUC4 in tumor
progression.
MUC4 expression was largely confined to the apical surface of
the normal breast epithelium (Figures 6a to 6c). The observed
luminal staining most likely results from shed epithelial cells or
glycocalyx, common in non-lactating breast tissue [14]. Similar
staining characteristics were noted in hyperplastic breast tis-
sues (not shown). Primary breast carcinoma frequently exhib-
ited significantly less MUC4 than normal tissue from the same
patient (compare Figures 6c and 6d) using endothelial stain-
ing as an internal positive control (arrows). MUC4 localization
in primary tumors was generally consistent throughout a given
sample, but the pattern differed from one sample to the next.
MUC4 immunoreactivity was most frequently diffusely cyto-
plasmic, occasionally membranous, but rarely nuclear. Expres-
sion of several mucins, including MUC4 in other tissue types,
has been reported as cytoplasmic or membranous [32-34].
Often lymph node metastatic lesions exhibited higher MUC4
staining than patient-matched primary tumors (compare Fig-
ures 6e and 6f and Figures 6g and 6h). Notably, even with the
relatively modest core sizes, tumor emboli were often
observed within lymphovascular spaces of lymph node tissue
(Figures 6h and 6i, arrowheads), where both the vasculature
and the adherent epithelial emboli stained positively for
MUC4.
MUC4 promotes aggressive properties of breast tumor 
cells
The strong tendency for MUC4 to become re-expressed in
metastatic lesions relative to matched primary tumors raises
the possibility that MUC4 expression promotes cellular prop-
erties related to metastasis. To test this, we examined the
impact of MUC4 knockdown on metastasis-associated prop-
erties of JIMT-1 cells. A significant barrier to metastasis is
anoikis, or cell death associated with the loss of cellular adhe-
sion to a substratum or other cells. We observed that shRNA-
mediated depletion of MUC4 reproducibly elevated the prob-
ability that JIMT-1 cells will undergo death by almost three-fold
when grown in suspension, but did not reproducibly affect the
viability of adherent cells (Figure 7a) because essentially the
Figure 4
Characterization of 1G8s for immunohistochemistry Characterization of 1G8s for immunohistochemistry. (a) A375-Rep8 
cells (24) were treated with or without tetracycline to induce Muc4 
expression, and cells were harvested and lysates were blotted with 
1G8s and anti-tubulin (left panels), or cells were fixed in formalin, 
embedded in paraffin and analyzed by immunohistochemistry using 
1G8s. (b) MCF10A-hMUC4/Y cells were treated with or without tetra-
cycline to induce Muc4 expression, lysed and blotted with 1G8s and 
anti-tubulin (left panels), or analyzed by immunohistochemistry using 
1G8s. (c) JIMT-1 cells stably transduced with MUC4-directed shRNA 
(KD) or scramble (scr) were blotted with 1G8s and anti-tubulin (upper 
panels), or analyzed by immunohistochemistry using 1G8s.
Figure 5
1G8s staining of breast tumor samples, illustrating examples of the 0 to 3+ staining scale employed 1G8s staining of breast tumor samples, illustrating examples of the 0 to 3+ staining scale employed.Breast Cancer Research    Vol 11 No 5    Workman et al.
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entire adherent population is viable. Moreover, MUC4 knock-
down limited the progression of both adherent and suspended
JIMT-1 cells through the cell cycle (Figure 7b), suggesting that
MUC4 may promote the proliferation of metastasizing breast
tumor cells. Finally, MUC4 knockdown impaired the motility of
JIMT-1 cells (Figure 7c). JIMT-1 cells appear not to be signifi-
cantly invasive, so MUC4 knockdown had little impact on inva-
siveness (not shown). Coupled with previous observations
that MUC4 is potently anti-adhesive [24] and may be capable
of allowing individual cells to more easily break away from the
primary tumor mass, these observations suggest that MUC4
expression also allows those cells to more easily migrate to the
vasculature to initiate metastasis, survive in circulation, and
proliferate when not physically attached to tissue.
Discussion
A number of studies underscore the notion that MUC4 may be
capable of contributing to the malignant properties of tumor
cells. Inducible expression of rat MUC4 in human A375
melanoma cells has been demonstrated to augment primary
tumor growth [25] and metastasis [26] in a nude mouse
xenograft model. In vitro studies using the inducible rat MUC4
expression model and other cell lines indicate that ErbB2-
dependent and ErbB2-independent signaling activities of
MUC4 contribute to its proliferative and anti-apoptotic func-
tions [9,11,12,35]. Moreover, the abundant O-linked glyco-
sylation of MUC4 contributes to its anti-adhesive properties
[24], masks antigens on tumor cell surfaces and inhibits cell
killing by cytotoxic lymphocytes [36]. Collectively, these obser-
vations raise the possibility that dysregulation of MUC4 in
patient tumors can confer properties to tumor cells that pro-
mote tumor progression.
Although ample in vitro and nude mouse model evidence
exists that dysregulated MUC4 can potentially play a role in
human tumors, evidence that it does so has been harder to
obtain. The most convincing data come from pancreatic carci-
nomas, where normal tissue lacks MUC4 and expression
increases with the progression of the disease [37]. MUC4 is
commonly expressed in pancreatic tumor cell lines, and knock-
down has been demonstrated to suppress pancreatic tumor
cell proliferation, survival, and invasive properties [38]. How-
ever, involvement of MUC4 in the progression of other tumor
types has been more difficult to assess because normal tis-
sues express abundant MUC4 and because cell lines often
rarely express the protein. In these cases MUC4 overexpres-
sion relative to normal tissue, MUC4 mislocalization in cells
that have lost their polarity, or re-expression of lost MUC4 in
more advanced tumor stages, can all markedly impact disease
progression but can be difficult to detect and characterize.
Another significant challenge in discerning MUC4 involvement
in the progression of many tumor types concerns its detection.
Early studies employed in situ hybridization methods to detect
Table 1
Muc4 expression in human breast tissue by immunohistochemistry with 1G8s. Tissue samples from normal breast tissue, primary 
tumors or lymph node metastases were assigned a value of 0 to 3+ based on their MUC4 staining intensity with 1G8s. Statistical 
analysis of MUC4 staining intensities is presented for individual samples (upper panel) and patient-matched samples (lower panel).
Tissue type - individual Number of cases (%)a Composite score (mean ± 
standard error)
P value Norm vs Prim P value Prim vs Met
Normal 110 (92.4) 2.01 ± 0.09 < 0.001
Hyperplastic 26 (100)
Ductal carcinoma in situ 14 (85.7)
Primary tumorb 264 (79.5) 1.30 ± 0.06
Primary lobular carcinoma 22 (68.1)
Metastasis 48 (84) 1.63 ± 0.15 0.033
Tissue type - paired Number of pairs Composite score (mean ± 
standard error)
P values McNemar's test
Normal with matched primary 73 < 0.001
Normal 2.07 ± 0.10
Primary 1.28 ± 0.12
Primary with matched 
metastasisc
43 0.0025
Primary 1.10 ± 0.21
Metastasis 1.95 ± 0.41
a. Percent of patient samples that had 1+ stain or greater on a scale from 0 to 3+.
b. Primarily consists of invasive ductal carcinoma-NOS, but also includes invasive lobular carcinoma, micropapillary and mucinous carcinomas.Available online http://breast-cancer-research.com/content/11/5/R70
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the MUC4 message in normal and tumor tissue [39,40].
Although such studies provide information on where MUC4
protein can possibly be expressed, observations that rat
MUC4 may be post-transcriptionally and post-translationally
regulated by factors such as transforming growth factor-β and
other basement membrane components [41] raise questions
as to the extent to which this method can be used to accu-
rately assess MUC4 protein expression by tissues. More
recently immunohistochemical methods have been employed
to assess MUC4 expression. The antibodies most commonly
employed are 8G7, raised to a peptide within the repeating
units of the O-glycosylation domain, and 1G8, originally raised
to rat MUC4β but more recently demonstrated to react with
human protein. In our hands, both of these antibodies obtained
from commercial sources recognized bands that could not be
knocked down with MUC4-specific RNA interference in immu-
noblotting experiments, raising the possibility that staining
observed in immunohistochemical studies with these antibod-
ies includes unrelated proteins. Moreover, as 8G7 is raised to
an epitope whose post-translational modification could inter-
fere with immunoreactivity, this antibody may preferentially rec-
ognize an underglycosylated subset of MUC4 in tissues.
In our study we develop a preparation of the 1G8 antibody that
specifically recognizes MUC4β by immunoblotting, and whose
immunoreactivity with cultured MUC4-positive breast cancer
cells by immunohistochemical staining is markedly sup-
pressed when MUC4 expression is knocked down. The rea-
son underlying the difference in specificities between the
commercial and hybridoma sources is unknown, but may be
related to differences in antibody production. This reagent
allowed us to localize MUC4 to the luminal surface of normal
Figure 6
MUC4 expression in human breast tissue MUC4 expression in human breast tissue. Tissue microarrays were analyzed by immunohistochemistry using 1G8s. (a) Normal human breast of 
patient number 1 at 200×. (b) High magnification (500×) of patient number 1 normal breast, highlighting strong apical staining of MUC4 in epithelia, 
and endothelial staining (black arrow) as an internal control. (c) Normal human breast tissue of patient number 2 at 200×, exhibiting cytoplasmic 
staining patterns. (d) Matched primary invasive ductal carcinoma (200×) of patient number 2. Note the MUC4-positive blood vessels (black arrows), 
but the neoplastic epithelial cells are negative. (e) Primary invasive ductal carcinoma (200×) of patient number 3 with positive endothelial cells noted 
as black arrows, but no detectable neoplastic epithelial cell staining. (f) Matched metastatic breast carcinoma of the lymph node of patient number 
3. Note increased staining intensity of MUC4. (g) Primary invasive ductal carcinoma (500×) of patient number 4 with many mitotic figures. (h) 
Matched metastatic tissue from patient number 4 showing a tumor embolus (500×, arrowhead). Note the MUC4-positive tumor cells within the lym-
phovascular space. (i) Metastatic breast tumor of patient number 5 (200×). Note the lymphocytes and intensely positive vessels (black arrows). 
Three tumor emboli are noted (arrowheads).Breast Cancer Research    Vol 11 No 5    Workman et al.
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breast epithelium, observations that recapitulate those made
with rat mammary glands [42]. Unexpectedly, we observed
that MUC4 expression levels tended to be suppressed in pri-
mary tumors relative to normal tissue, whether examining
patient-matched sample pairs or individual patient samples.
The simplest explanation for these observations is that MUC4
expression is a marker for fully differentiated breast epithelium,
and dedifferentiated breast tumor cells are impaired in their
ability to support MUC4 expression. MUC4 expression is
regained in many lymph node metastases relative to primary
breast tumor, raising the possibility that the presence of
MUC4 confers an advantage to metastasizing tumor cells.
Consistent with these observations, our MUC4 knockdown
experiments reveal that its expression contributes to the
aggressive properties of breast tumor cells. Interestingly, a
recent study found that MUC4 expression levels in primary
prostate tumors is lower on average than in normal or benign
hyperplastic tissue [43], although patient-matched tissues
were not employed. In light of our findings it would be interest-
ing to determine whether prostate metastases similarly regain
MUC4 expression and contribute to prostate tumor cell
aggressiveness. Such observations would lend support to the
broader notion that MUC4 presence in metastasizing carcino-
mas contributes to tumor malignancy.
Collectively, the accumulated data point to a scenario where
re-expression of MUC4 by a subset of primary breast tumor
cells promotes their metastasis via several mechanisms. Over-
expression or mislocalization of heavily glycosylated MUC4 by
a subset of cells within a primary tumor population can contrib-
ute to the disruption of cell-cell and cell-matrix interactions,
which in turn facilitates the migration of tumor cells away from
the primary tumor and into the circulatory or lymphatic sys-
tems. Moreover, the anti-apoptotic signaling properties of
MUC4 [12] can minimize the chances that primary tumor cells
that have lost adhesion and are undergoing metastasis will
undergo anoikis. Based on these arguments, we would predict
that MUC4 overexpression might be particularly prevalent in
actively metastasizing cells such as circulating tumor cells, or
in metastatic cells that accumulate in abdominal or pleural
effusions. Indeed, given the potent anti-adhesive properties of
MUC4, these tumor cell populations could express very high
Figure 7
MUC4 expression promotes breast tumor cell aggressiveness MUC4 expression promotes breast tumor cell aggressiveness. (a) Death of adherent or suspended JIMT-1 cells stably transduced with scrambled 
or MUC4-directed shRNA was measured by sub-G1 DNA content. The fold increase in the probability that the cells will undergo death in the 
absence of MUC4 relative to MUC4 expression was calculated and plotted for adherent and suspended conditions. 1 represents no effect, and 5 
represents a 5-fold higher probability as calculated by odds ratio, with a P value of < 0.001. Error bars indicate the 95% confidence interval for the 
population, and the points indicate the center of the confidence interval. (b) JIMT-1 cells described in (a) were analyzed for DNA content by fluores-
cent-activated cell sorting, and the percentage of cells outside G1 phase of the cell cycle (excluding sub-G1) were plotted. (c) Migration of JIMT-1 
cells stably transduced with scrambled and MUC4-directed shRNAs was determined by Boyden chamber assay. * P < 0.05.Available online http://breast-cancer-research.com/content/11/5/R70
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levels of MUC4 protein, which may again be suppressed to
some degree upon metastatic seeding of a solid target tissue.
Finally, if expression facilitates metastasis then MUC4 could
ultimately serve as an independent prognostic marker of the
most aggressive tumors. Patients whose primary tumors
exhibit elevated MUC4 expression could be at higher risk of
developing metastases than those whose MUC4 remains sup-
pressed. However, it should be noted that MUC4 expression
by a small subset of cells within the primary tumor mass may
be sufficient to facilitate metastasis, and this population could
easily be overlooked by immunohistochemical analysis. More-
over, as we have observed that pre-malignant atypical hyper-
plasias and DCIS have not yet suppressed their MUC4
expression, such studies would necessarily need to couple
MUC4 expression analysis with careful pathological
evaluation.
Conclusions
The observations described here provide strong evidence that
MUC4 becomes re-expressed during the transition of primary
breast tumor to metastatic lesion. Moreover, MUC4 re-expres-
sion enhances malignancy by promoting the survival and pro-
liferation of non-adherent actively metastasizing cells. These
observations pave the way for the assessment of MUC4
expression in primary breast tumor samples as a marker for
metastatic disease using the 1G8 antibody.
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